The North America Human Microbiome Market is expected to witness market growth of 31.4% CAGR during the forecast period (2022-2028).
The intestinal microbiota contributes significantly to the nutritional needs of its host. Complex dietary elements that are indigestible (complex carbohydrates) are aggressively broken down by these organisms, making complex food ingredients readily available for digestion and absorption and hence, play a crucial role in maintaining the health of the host. These factors are propelling the demand for synthetic human microbiome and therefore, the growth of the human microbiome market is being augmented.
Many microbes invade humans, with non-human cells of nearly the same order of magnitude as human cells. Some bacteria that colonize people are commensal, indicating they coexist with humans without harming them, whereas others have a mutualistic connection with them. Non-pathogenic bacteria, on the other hand, can cause harm to human hosts by the metabolites they create, such as trimethylamine, which the human body transforms to trimethylamine N-oxide through FMO3-mediated oxidation. Certain microbes carry out actions that are known to benefit the human host, but the majority of their functions are unidentified. Those that are estimated to be present and do not cause disease in typical circumstances are referred to as normal flora or normal microbiota.
There is a robust prevalence of obesity in the United States. According to the Harvard TH Chan's School of Public Health, obesity prevalence in the United States was 41.9% from 2017 to 2020. Obesity prevalence in the United States climbed from 30.5% to 41.9% between 1999 and 2020. The prevalence of severe obesity grew from 4.7% to 9.2% throughout this time. Heart disease, type 2 diabetes, stroke, along with some types of cancer are all linked to obesity. These are some of the most common causes of preventable death. In 2019, the estimated yearly medical cost of obesity in the United States was about $173 billion. Adults with obesity had medical costs that were $1,861 more than those with a healthy weight. The highest age-adjusted prevalence of obesity was seen among non-Hispanic Black adults (49.9%), preceded by Hispanic adults (45.6%), non-Hispanic White adults (41.4%), and non-Hispanic Asian adults (16.1%). Obesity was shown to be prevalent in adults aged 20 to 39 years, 44.3% in adults aged between 40 to 59 years, and 41.5% in people aged 60 and above.
The US market dominated the North America Human Microbiome Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $307.7 million by 2028. The Canada market is experiencing a CAGR of 34.4% during (2022 - 2028). Additionally, The Mexico market is expected to exhibit a CAGR of 33.2% during (2022 - 2028).
Based on Product, the market is segmented into Drugs, Diagnostic Tests, Probiotics, Prebiotics, and Others. Based on Disease Type, the market is segmented into Infectious Diseases, Endocrine & Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Others. Based on Technology, the market is segmented into Genomics, Proteomics and Metabolomics. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on Type, the market is segmented into Microbiome Consortia Transplantation (FMT), Peptide, Live Biotherapeutic Product and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome.
The intestinal microbiota contributes significantly to the nutritional needs of its host. Complex dietary elements that are indigestible (complex carbohydrates) are aggressively broken down by these organisms, making complex food ingredients readily available for digestion and absorption and hence, play a crucial role in maintaining the health of the host. These factors are propelling the demand for synthetic human microbiome and therefore, the growth of the human microbiome market is being augmented.
Many microbes invade humans, with non-human cells of nearly the same order of magnitude as human cells. Some bacteria that colonize people are commensal, indicating they coexist with humans without harming them, whereas others have a mutualistic connection with them. Non-pathogenic bacteria, on the other hand, can cause harm to human hosts by the metabolites they create, such as trimethylamine, which the human body transforms to trimethylamine N-oxide through FMO3-mediated oxidation. Certain microbes carry out actions that are known to benefit the human host, but the majority of their functions are unidentified. Those that are estimated to be present and do not cause disease in typical circumstances are referred to as normal flora or normal microbiota.
There is a robust prevalence of obesity in the United States. According to the Harvard TH Chan's School of Public Health, obesity prevalence in the United States was 41.9% from 2017 to 2020. Obesity prevalence in the United States climbed from 30.5% to 41.9% between 1999 and 2020. The prevalence of severe obesity grew from 4.7% to 9.2% throughout this time. Heart disease, type 2 diabetes, stroke, along with some types of cancer are all linked to obesity. These are some of the most common causes of preventable death. In 2019, the estimated yearly medical cost of obesity in the United States was about $173 billion. Adults with obesity had medical costs that were $1,861 more than those with a healthy weight. The highest age-adjusted prevalence of obesity was seen among non-Hispanic Black adults (49.9%), preceded by Hispanic adults (45.6%), non-Hispanic White adults (41.4%), and non-Hispanic Asian adults (16.1%). Obesity was shown to be prevalent in adults aged 20 to 39 years, 44.3% in adults aged between 40 to 59 years, and 41.5% in people aged 60 and above.
The US market dominated the North America Human Microbiome Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $307.7 million by 2028. The Canada market is experiencing a CAGR of 34.4% during (2022 - 2028). Additionally, The Mexico market is expected to exhibit a CAGR of 33.2% during (2022 - 2028).
Based on Product, the market is segmented into Drugs, Diagnostic Tests, Probiotics, Prebiotics, and Others. Based on Disease Type, the market is segmented into Infectious Diseases, Endocrine & Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Others. Based on Technology, the market is segmented into Genomics, Proteomics and Metabolomics. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on Type, the market is segmented into Microbiome Consortia Transplantation (FMT), Peptide, Live Biotherapeutic Product and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Drugs
- Diagnostic Tests
- Probiotics
- Prebiotics, and
- Others
By Disease Type
- Infectious Diseases
- Endocrine & Metabolic Disorders
- Gastrointestinal Diseases
- Cancer, and
- Others
By Technology
- Genomics
- Proteomics
- Metabolomics
By Application
- Therapeutics
- Diagnostics
By Type
- Microbiome Consortia Transplantation (FMT)
- Peptide
- Live Biotherapeutic Product
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Seres Therapeutics, Inc.
- 4D pharma plc
- OptiBiotix Health Plc
- Synlogic, Inc.
- Second Genome, Inc.
- Vedanta Biosciences, Inc.
- Finch Therapeutics Group, Inc.
- Ferring Holdings SA
- Enterome
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Human Microbiome Market by Product
Chapter 4. North America Human Microbiome Market by Disease Type
Chapter 5. North America Human Microbiome Market by Technology
Chapter 6. North America Human Microbiome Market by Application
Chapter 7. North America Human Microbiome Market by Type
Chapter 8. North America Human Microbiome Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Seres Therapeutics, Inc.
- 4D pharma plc
- OptiBiotix Health Plc
- Synlogic, Inc.
- Second Genome, Inc.
- Vedanta Biosciences, Inc.
- Finch Therapeutics Group, Inc.
- Ferring Holdings SA
- Enterome
Methodology
LOADING...
